US2015072028A1PendingUtilityA1

Extracts and isolated compounds from cakile arabica for treatment of ulcer

54
Assignee: UNIV KING SAUDPriority: Sep 12, 2013Filed: Sep 4, 2014Published: Mar 12, 2015
Est. expirySep 12, 2033(~7.1 yrs left)· nominal 20-yr term from priority
Inventors:Awaad Amani ShafeekReham Moustafa El-MeligyMohammed Sobhy MarzoukShroog Mohamed Alotaiby
C07C 67/58C07C 67/56C07C 51/42A61K 31/225B01D 15/426A61P 1/04A61K 36/31A61K 9/0053A61K 31/22C07C 51/47A61K 2236/00A61K 2236/33C11B 1/10A61K 31/20B01D 11/0288B01D 11/0292C07C 67/48
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to extracts, compounds isolated from Cakile arabica for use in the treatment of ulcer and to pharmaceutical compositions thereof.

Claims

exact text as granted — not AI-modified
1 . Extract from a plant material of  Cakile arabica  for use in the treatment of ulcer. 
     
     
         2 . Extract according to  claim 1 , wherein the extract is an alcoholic extract, preferably is an ethanolic extract. 
     
     
         3 . Extract according to  claim 1 , wherein the plant material comprises the aerial parts of  Cakile arabica.    
     
     
         4 . Compound selected from tetracosanoic acid and/or 4-hydroxy-5-n-butoxy-5-oxopentanoic acid for use in the treatment of ulcer. 
     
     
         5 . Method for isolating tetracosanoic acid and/or 4-hydroxy-5-n-butoxy-5-oxopentanoic acid from  Cakile arabica , comprising the steps:
 a. extracting a plant material of  Cakile arabica  to obtain an extract;   b. concentrating the extract to obtain a concentrate;   c. chromatographing the concentrate into fractions; and   d. isolating fractionated compounds.   
     
     
         6 . Method according to  claim 5 , wherein the plant material comprises the aerial parts of  Cakile arabica.    
     
     
         7 . Method according to  claim 5 , wherein extracting is carried out by using at least one organic solvent. 
     
     
         8 . Method according to  claim 7 , wherein the organic solvent is selected from the group consisting of petroleum ether, heptane, hexane, ethanol, isopropanol, methanol and mixtures thereof, preferably is ethanol. 
     
     
         9 . Method according to  claim 5 , wherein chromatographing is carried out by means of thin layer chromatography (TLC) and/or column chromatography. 
     
     
         10 . Method according to  claim 5 , wherein the eluent used for chromatographing is petroleum ether, heptane, ethanol, methanol, benzene, diethyl ether, chloroform, dichloromethane, water and/or mixtures thereof. 
     
     
         11 . Method according to  claim 5 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         12 . Pharmaceutical composition comprising an extract according to  claim 1 . 
     
     
         13 . Pharmaceutical composition according to  claim 12 , formulated for oral administration. 
     
     
         14 . Extract according to  claim 2 , wherein the plant material comprises the aerial parts of  Cakile arabica.    
     
     
         15 . Method according to  claim 6 , wherein extracting is carried out by using at least one organic solvent. 
     
     
         16 . Method according to  claim 6 , wherein chromatographing is carried out by means of thin layer chromatography (TLC) and/or column chromatography. 
     
     
         17 . Method according to  claim 7 , wherein chromatographing is carried out by means of thin layer chromatography (TLC) and/or column chromatography. 
     
     
         18 . Method according to  claim 8 , wherein chromatographing is carried out by means of thin layer chromatography (TLC) and/or column chromatography. 
     
     
         19 . Method according to  claim 6 , wherein the eluent used for chromatographing is petroleum ether, heptane, ethanol, methanol, benzene, diethyl ether, chloroform, dichloromethane, water and/or mixtures thereof. 
     
     
         20 . Method according to  claim 7 , wherein the eluent used for chromatographing is petroleum ether, heptane, ethanol, methanol, benzene, diethyl ether, chloroform, dichloromethane, water and/or mixtures thereof. 
     
     
         21 . Method according to  claim 8 , wherein the eluent used for chromatographing is petroleum ether, heptane, ethanol, methanol, benzene, diethyl ether, chloroform, dichloromethane, water and/or mixtures thereof. 
     
     
         22 . Method according to  claim 9 , wherein the eluent used for chromatographing is petroleum ether, heptane, ethanol, methanol, benzene, diethyl ether, chloroform, dichloromethane, water and/or mixtures thereof. 
     
     
         23 . Method according to  claim 6 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         24 . Method according to  claim 7 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         25 . Method according to  claim 8 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         26 . Method according to  claim 9 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         27 . Method according to  claim 10 , wherein the stationary phase used for chromatographing is silica gel and/or aluminum oxide. 
     
     
         28 . Pharmaceutical composition comprising an extract according to at least one of the compounds according to  claim 4 .

Join the waitlist — get patent alerts

Track US2015072028A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.